Last reviewed · How we verify
GX-I7
GX-I7 is a recombinant human fibroblast growth factor 21 (FGF21) protein.
GX-I7 is a recombinant human fibroblast growth factor 21 (FGF21) protein. Used for Type 2 diabetes.
At a glance
| Generic name | GX-I7 |
|---|---|
| Also known as | rhIL-7-hyFc, Efineptakin alfa, Efineptakin alfa NT-I7, NT-I7, TJ107 |
| Sponsor | Genexine, Inc. |
| Drug class | FGF21 protein |
| Target | FGF21 receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
It works by mimicking the action of FGF21, a hormone involved in glucose and lipid metabolism, to improve glycemic control and reduce body weight.
Approved indications
- Type 2 diabetes
Common side effects
- Injection site reaction
Key clinical trials
- HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy (PHASE2)
- Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer (PHASE2)
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma (PHASE2)
- NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery (PHASE1)
- NT-I7 for Kaposi Sarcoma in Patients With or Without HIV (PHASE1)
- Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. (PHASE1)
- Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) (PHASE1, PHASE2)
- GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GX-I7 CI brief — competitive landscape report
- GX-I7 updates RSS · CI watch RSS
- Genexine, Inc. portfolio CI